-
Laboratory Performance of the DopaFuse® Delivery System
-
Lack of Notable Skin Reactions from a Novel Levodopa/Carbidopa Prodrug after 10 Days of Repeated 24-Hour Continuous Subcutaneous Infusion at the Same Administration Site
-
Language characteristics of picture description task by Hebrew speaking patients with Parkinson’s disease
-
Language disorders in Progressive Supranuclear Palsy: an underestimated condition?
-
Large Sample Study on Paroxysmal Kinesigenic Dyskinesia: Genotype-Phenotype Analysis and Diagnosis Recommendations
-
Late onset idiopathic cerebral edema associated with deep brain stimulation
-
LATE ONSET OF PARKINSON’S DISEASE
-
Left STN DBS And Right CZI DBS In A Patient With Tremor-Predominant Parkinson’s Disease
-
Levocarb-induced diplopia in idiopathic Parkinson’s disease: a case report
-
Levodopa Effects on Visuospatial Working Memory in Parkinson’s Disease
-
Levodopa Induced dyskinesia in patients with Parkinson’s disease and polymorphisms gene DRD3 dopamine receptor
-
Levodopa response in later stages of Parkinson’s disease: a case-control study
-
Levodopa-carbidopa intestinal gel infusion: a video analysis of long-term effect on gait and posture
-
Levodopa-responsive tremor in a young child as a delayed complication of osmotic demyelination from severe hypernatremia
-
Levodopa/carbidopa Intestinal Gel in Treatment of Non-Motor Symptoms in Advanced Parkinson’s Disease
-
Life expectancy with and without Parkinson’s disease in the general population
-
Limitations of Curcumin as a Therapeutic Agent in Rotenone Induced Dopaminergic Neurodegeneration: Insights from Drosophila Model of Parkinson’s Disease
-
Lip movement contribution in speech production of persons with Parkinson’s Disease
-
Liquid Levodopa/Carbidopa – An underutilized, cost effective treatment of advanced Parkinson’s disease in the developing world
-
Local anesthesia vs general anesthesia in STN-dDBS operation: a clinical comparison of the outcome of patients with advanced Parkinson’s disease
-
Local beta band synchronization predicts clinically-selected deep brain stimulation contact in Parkinson’s disease patients
-
Local field potential recordings in the human pallidum using externalized directional DBS leads
-
Long term evolution of ventilatory function in Parkinson’s disease
-
Long Term Follow Up Following Multidisciplinary Inpatient Rehabilitation for Functional Movement Disorders
-
Long term outcome of STN-DBS for Parkinson Disease patients using Directional mode setting programs
-
Long-term adherence with wearing a multi-sensor watch in the Personalized Parkinson Project
-
Long-term apomorphine infusion (APO) users versus short-term APO users: What is the reason to discontinue therapy? A multi-centre study
-
Long-term changes in myocardial sympathetic innervation and function in synucleinopathies
-
Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson’s disease
-
Long-term effects of bilateral subthalamic nucleus stimulation on sleep in patients with Parkinson’s disease
-
Long-Term Effects of LPS and Alcohol in Rats: A Model of Neuro-Degenerative Disease
-
Long-term follow up of unilateral focused ultrasound subthalamotomy for the treatment of motor features in asymmetric PD
-
Long-term impact of Levodopa Carbidopa Intestinal Gel (LCIG) on reducing “Off” time: Results from a systematic review of studies with ≥ 12 months of follow-up
-
Long-term levodopa-carbidopa intestinal infusion in Parkinson’s disease: survival and mortality
-
Long-term Motor and Non-motor Outcomes in Parkinson’s Disease Following Deep Brain Stimulation
-
Long-Term Outcomes in Patients with Tardive Dyskinesia who Were Early Responders with Valbenazine
-
Long-Term Outcomes with Valbenazine 40 mg/day in Adults with Tardive Dyskinesia
-
Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease (PD) patients with persistent motor fluctuations: results of the 1-year open-label phase of the TOLEDO study
-
Long-term safety and efficacy of rimabotulinumtoxinB in the treatment of adult sialorrhea
-
Long-term treatment of cervical dystonia with abobotulinumtoxinA
-
Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia: Results From an Open-Label Extension Study
-
Long-term Yearly Trends of Feeding Tube Placement in Neurodegenerative Disorders
-
Longitudinal analysis of disease progression in a large PKAN cohort in the Dominican Republic
-
Longitudinal Analysis of the Corticospinal tract microstructure in Parkinson’s Disease Patients
-
Longitudinal analysis of the modified Hoehn and Yahr disease stage in PD-1101, a Phase 1b clinical study of VY-AADC01
-
Longitudinal analysis of the relation between trajectories of dopaminergic agonists use and BMI in Parkinson’s disease
-
Longitudinal assessment of genetic determinants of cognitive decline in Parkinson’s disease
-
Longitudinal Change of Substantia Nigra Hyperechogenicity in Parkinson’s Disease Cohort
-
Longitudinal Cortical Changes Associated with Apathy in Parkinson’s Disease
-
Longitudinal CSF-profile and brain pathology mirrors clinical course of LRRK2-Related Parkinson’s Disease
-
Longitudinal digital observation of the holistic quality of the life of patients with Parkinson’s disease
-
Longitudinal DNA methylation changes, in blood, associated with Parkinson’s disease progression
-
Longitudinal progression of spatiotemporal parameters of turning in idiopathic Parkinson’s disease patients with Freezing of Gait
-
Longstanding cervical dystonia followed by parkinsonism – coincidence, risk factor or syndromic association?
-
Looking “cherry red spot myoclonus” in the eyes
-
Low and high beta band activity in the primary sensorimotor cortex is diminished by ipsilateral subthalamic stimulation in Parkinsonian patients
-
Low doses of scopolamine exacerbates dementia among Drosophila with Parkinson’s disease pathophysiology
-
Lower urinary tract symptoms and urodynamic findings in SCAs
-
LRP10 variants and Parkinson’s disease in the Chinese population
-
LY-341,495, an mGlu2/3 antagonist, abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2/3 orthosteric agonist LY-354,740 in the MPTP-lesioned marmoset
-
Lymphocyte Senescence in Parkinson’s Disease
2019 International Congress
September 22-26, 2019. Nice, France.